15026-17-2

Usage

Uses

Used in Pharmaceutical Industry:
Mono-tert-butyl succinate is used as a reagent for the synthesis of fluorinated β2and β3-amino acids, which are important building blocks in the development of new pharmaceutical compounds. These amino acids can be incorporated into peptide and protein structures, potentially leading to the creation of novel drugs with improved properties.
Used in Enzyme Inhibition:
Mono-tert-butyl succinate is also used as an inhibitor of α-chymotrypsin, a serine protease enzyme that plays a crucial role in the digestive process. By inhibiting this enzyme, it can help regulate the breakdown of proteins in the body, which may have therapeutic applications in conditions where protein degradation is a concern.
General Description:
Mono-tert-butyl succinate can be prepared by refluxing a mixture of succinic anhydride and N-hydroxyl succinimide in the presence of dimethylaminopyridine and triethylamine in tert-butanol and toluene. This synthesis method allows for the efficient production of the compound, which can then be utilized in various applications across different industries.

Synthesis Reference(s)

Tetrahedron Letters, 32, p. 4239, 1991 DOI: 10.1016/S0040-4039(00)92137-3

InChI:InChI=1/C8H14O4/c1-8(2,3)12-7(11)5-4-6(9)10/h4-5H2,1-3H3,(H,9,10)

Upstream product

• 926-26-1 di-tert-Butyl succinate 
• 108-30-5 succinic acid anhydride 
• 75-65-0 tert-butyl alcohol 
• 540-88-5 acetic acid tert-butyl ester 
• 79-08-3 bromoacetic acid 
• 15026-16-1 1-benzyl 4-tert-butyl succinate 
• 59524-02-6 N-tert-butoxycarbonyl-L-serine benzyl ester 
• 1663-39-4 tert-Butyl acrylate 
• 590-29-4 potassium formate 
• 3495-36-1 cesium formate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 110-15-6 succinic acid 
• 1207973-75-8 lithium tert-butyl acetate 
• 64916-53-6 bromoacetic acid lithium salt 

Downstream Products

• 110-15-6 succinic acid 
• 115-11-7 isobutene 
• 141437-91-4 3-[2-(Benzyloxycarbonylmethyl-carbamoyl)-3-phenyl-propylsulfanylcarbonyl]-propionic acid tert-butyl ester 
• 234081-55-1 N-(1,2-bis-hexadecylcarbamoyl-ethyl)-2-(3-tert-butoxycarbonyl-propionylamino)-succinamic acid benzyl ester 
• 125470-05-5 3-benzyl-4-(tert-butoxy)-4-oxobutanoic acid 
• 59854-12-5 tert-butyl 4-hydroxybutyrate 
• 879216-19-0 5-[4-(5,5-dimethyl-4-oxo-hexanoylamino)-phenyl]-isoxazole-3-carboxylic acid methyl ester 
• 886573-99-5 3,5-bis-[3-(3-tert-butoxycarbonyl-propionylamino)-propoxy]-benzoic acid allyl ester 
• 432037-43-9 tert-butyl (chloromethyl) succinate 
• 1239468-42-8 4-[(benzyloxy)amino]-4-oxobutanoic acid tert-butyl ester 
• 1305319-50-9 1,4,8,11,15,18-hexabutoxy-23-[3-(tert-butylsuccinatoxymethyl)phenoxy]phthalocyanine 
• 1269638-21-2 succinic acid tert-butyl pentafluorophenyl ester 
• 1663-39-4 tert-Butyl acrylate 

Relevant academic research and scientific papers

Molecular umbrella as a nanocarrier for antifungals

A molecular umbrella composed of two O‐sulfated cholic acid residues was applied for the construction of conjugates with cispentacin, containing a “trimethyl lock” (TML) or o‐dithiobenzylcarbamoyl moiety as a cleavable linker. Three out of five conjugates

SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-a]ISOQUINOLIN-2-OL COMPOUNDS, THEIR SYNTHESIS, AND USE THEREOF

The invention relates to substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol compounds, their synthesis, pharmaceutical compositions containing them, and methods of using them in the treatment of disorders benefiting from inhibition of vesicular monoamine transporter 2 (VMAT2).

Photoredox Activation of Formate Salts: Hydrocarboxylation of Alkenes via Carboxyl Group Transfer

A photoredox activation mode of formate salts for carboxylation was developed. Using a formate salt as the reductant, carbonyl source, and hydrogen atom transfer reagent, a wide range of alkenes can be converted into acid products via a carboxyl group tra

Photoinduced Hydrocarboxylation via Thiol-Catalyzed Delivery of Formate across Activated Alkenes

Herein we disclose a new photochemical process to prepare carboxylic acids from formate salts and alkenes. This redox-neutral hydrocarboxylation proceeds in high yields across diverse functionalized alkene substrates with excellent regioselectivity. This operationally simple procedure can be readily scaled in batch at low photocatalyst loading (0.01% photocatalyst). Furthermore, this new reaction can leverage commercially available formate carbon isotologues to enable the direct synthesis of isotopically labeled carboxylic acids. Mechanistic studies support the working model involving a thiol-catalyzed radical chain process wherein the atoms from formate are delivered across the alkene substrate via CO2?- as a key reactive intermediate.

CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS

The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.

Control of conformation in α-helix mimicking aromatic oligoamide foldamers through interactions between adjacent side-chains

The design, synthesis and structural characterization of non-natural oligomers that adopt well-defined conformations, so called foldamers, is a key objective in developing biomimetic 3D functional architectures. For the aromatic oligoamide foldamer family

Bisubstrate inhibitors of nicotinamide N-methyltransferase (NNMT) with enhanced activity

Nicotinamide N-methyltransferase (NNMT) catalyzes the methylation of nicotinamide to form N-methylnicotinamide. Overexpression of NNMT is associated with a variety of diseases, including a number of cancers and metabolic disorders, suggesting a role for NNMT as a potential therapeutic target. By structural modification of a lead NNMT inhibitor previously developed in our group, we prepared a diverse library of inhibitors to probe the different regions of the enzyme's active site. This investigation revealed that incorporation of a naphthalene moiety, intended to bind the hydrophobic nicotinamide binding pocket via π-πstacking interactions, significantly increases the activity of bisubstrate-like NNMT inhibitors (half-maximal inhibitory concentration 1.41 μM). These findings are further supported by isothermal titration calorimetry binding assays as well as modeling studies. The most active NNMT inhibitor identified in the present study demonstrated a dose-dependent inhibitory effect on the cell proliferation of the HSC-2 human oral cancer cell line.

Hydrosilane-Promoted Facile Deprotection of tert-Butyl Groups in Esters, Ethers, Carbonates, and Carbamates

Combination of PdCl2 with 1,1,3,3-tetramethyldisiloxane in the presence of activated carbon was found to be an effective catalyst system for the cleavage reaction of C?O bond of O?t-Bu moieties. The present catalytic reaction offers a practical method for the deprotection of tert-butyl esters, tert-butyl ethers, O-Boc, and N-Boc derivatives under mild conditions. The addition of activated carbon in the reaction mixture was proved to be crucial for not only sustaining the catalytic activity but also trapping the palladium species after the reaction. (Figure presented.).

A MedChem toolbox for cereblon-directed PROTACs

A modular chemistry toolbox was developed for cereblon-directed PROTACs. A variety of linkers was attached to a CRBN ligand via the 4-amino position of pomalidomide. We used linkers of different constitution to modulate physicochemical properties. We equipped one terminus of the linker with a set of functional groups, e.g. protected amines, protected carboxylic acids, alkynes, chloroalkanes, and protected alcohols, all of which are considered to be attractive for PROTAC design. We also highlight different opportunities for the expansion of the medicinal chemists' PROTAC toolbox towards heterobifunctional molecules, e.g. with biotin, fluorescent, hydrophobic and peptide tags.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.